Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Instytut Farmakologii Polskiej Akademii NaukfiledCriticalUniwersytet Jagielloński
Priority to PL413428ApriorityCriticalpatent/PL231170B1/en
Publication of PL413428A1publicationCriticalpatent/PL413428A1/en
Publication of PL231170B1publicationCriticalpatent/PL231170B1/en
Ujawniono nową pochodną benzotiofenopiperazyny o nazwie [3-(4-benzo[b]tiofen-4-ylo-piperazin-1-ylo)-propylo]izochinolino-4-sulfonamid, która może być wykorzystywana jako modulator dopaminy i serotoniny, zwłaszcza jako środek terapeutyczny w leczeniu chorób ośrodkowego układu nerwowego, włączając depresję, manię, zaburzenia nastroju, zaburzenia lękowe, schizofrenię, zaburzenia związane z przyjmowaniem pokarmu, ADHD. Ponadto, ujawniony związek ma szerokie spektrum zastosowań jako środek terapeutyczny w chorobie Alzheimera, chorobie Parkinsona, chorobie Huntingtona, zespole Tourreta, autyzmie, napadach padaczkowych, lekozależności, otyłości, nie wykazując działań niepożądanych (sedacji) i wysokim bezpieczeństwie.A new benzothiophenopiperazine derivative named [3- (4-benzo [b] thiophen-4-yl-piperazin-1-yl) -propyl] isoquinoline-4-sulfonamide has been disclosed, which can be used as a dopamine and serotonin modulator, especially as an agent therapeutic in the treatment of central nervous system diseases, including depression, mania, mood disorders, anxiety disorders, schizophrenia, food related disorders, ADHD. In addition, the disclosed compound has a wide spectrum of uses as a therapeutic agent in Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourret syndrome, autism, epileptic seizures, drug dependence, obesity, without side effects (sedation) and high safety.
PL413428A2015-08-072015-08-07Derivative of benzothiophene piperazine and its applications
PL231170B1
(en)
Compounds derived from carboxamide; pharmaceutical composition that includes them, and their use as inhibitors of phosphodiesterase type 10a (pde10a) for the treatment of CNS disorders, schizophrenia, cognitive dysfunction related to schizophrenia, bipolar disorders, depression, cognitive dysfunction, cognitive disorders, behavioral disorders associated with Alzheimer's disease, obesity, huntington's disease and anxiety.
Compounds derived from 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes, phosphodiestearase 2 and / or 10 inhibitors; pharmaceutical composition; and its use for prevention or treatment of diseases of the nervous system, such as cognitive deficiency, dementia, anxiety disorders, enf. from Alzheimer, enf. from parkinson, others
Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor